 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX - Free Report) in a report released on Sunday morning. The firm issued a sell rating on the stock. OncoCyte Stock Down 1.7 % OncoCyte...

StockNews.com Begins Coverage on OncoCyte (NASDAQ:OCX)

StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX - Free Report) in a report issued on Sunday morning. The firm issued a sell rating on the stock.
OncoCyte Stock Performance
Shares of...

OncoCyte (NASDAQ:OCX) Research Coverage Started at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX  Get Free Report) in a research note issued to investors on Tuesday. The brokerage set a...

OncoCyte (NASDAQ:OCX) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX  Free Report) in a research report released on Wednesday. The firm issued a sell rating on the stock. Several other brokerages...

OncoCyte (NASDAQ:OCX) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX  Get Free Report) in a research report issued on Thursday. The firm set a sell rating on the stock. A number of...

StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX  Free Report) in a research report released on Friday. The brokerage issued a sell rating on the stock. Several other analysts...

StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX  Free Report) in a research report sent to investors on Friday morning. The firm issued a sell rating on the stock. A number of...

OncoCyte (NASDAQ:OCX) Receives New Coverage from Analysts at StockNews.com

IRVINE, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that CEO Josh Riggs will be presenting a corporate overview at...

Oncocyte to Present at the Sequire Investor Summit in Puerto Rico

Equities research analysts at StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX  Get Free Report) in a report released on Sunday. The firm set a sell rating on the...

StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX  Free Report) in a research report report published on Monday morning. The firm issued a sell rating on the stock. Other...

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.

Volume (M)	38,158.00
52-Wk High	$6.20
52-Wk Low	$2.08

OCX Oncocyte Corporation

About

Feed

News

Sentiment

Earnings

Fundamentals